Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. Kalinsky on Optical Imaging for HER2+ Breast Cancer

February 21st 2017

Kevin Kalinsky, MD, assistant professor of Medicine at Columbia University Medical Center, discusses the potential advantages of optical imaging for patients with HER2-positive breast cancer.

Olaparib Improves PFS in Phase III BRCA+ Breast Cancer Trial

February 17th 2017

The PARP inhibitor olaparib improved progression-free survival versus standard chemotherapy in patients with BRCA-positive, HER2-negative breast cancer, according to findings from the phase III OLYMPIAD trial.

Dr. Barcenas on Colestipol in Management of Neratinib Side Effects in HER2+ Breast Cancer

February 14th 2017

Carlos Barcenas, MD, assistant professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses managing neratinib-related side effects with colestipol (Colestid).

Breast Density Surpasses Other Risk Factors in Development of Breast Cancer

February 9th 2017

High breast density surpasses other known risk factors for developing breast cancer, including family history of the disease, personal history of benign lesions, and later-in-life childbirth, according to the results of a study published in JAMA Oncology.

Dr. Tjan-Heijnen on Results of DATA Study in Breast Cancer

February 9th 2017

Vivianne Tjan-Heijnen, MD, PhD, professor, Division of Medical Oncology, Department of Internal Medicine, Maastricht University Medical Center, discusses the results of the phase III DATA study.

Dr. White On RTOG 1119 Trial for Breast Cancer

February 9th 2017

Julia White, MD, professor of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, discusses RTOG-1119 trial for patients with breast cancer.

Nab-Paclitaxel Paired With Anti-PD-L1 Immunotherapies in TNBC Studies

February 8th 2017

Combination regimens that pair nab-paclitaxel with PD-L1 checkpoint blockade immunotherapy agents are emerging as a robust area of investigation in triple-negative breast cancer, bolstered by clinical trial results that establish the chemotherapeutic agent as an effective partner for other therapies.

Dr. Nangia on Challenges Facing Hair Loss Treatment for Breast Cancer

February 8th 2017

Julie R. Nangia, MD, assistant professor, Breast Center-Clinic, faculty senator, Baylor College of Medicine, discusses hair loss prevention treatment for patients with breast cancer.

O'Shaughnessy Predicts Rapid Evolution in TNBC Landscape

February 6th 2017

Joyce A. O’Shaughnessy, MD, addresses the key issues in breast cancer discussed at the 2017 OncLive® State of the Science Summit on Treatment of Metastatic Breast Cancer and shared her expert insight on where triple-negative breast cancer treatment is headed based on recent findings.

Patient Selection an Important Next Step in HER2+ Breast Cancer

February 4th 2017

Melanie E. Royce, MD, PhD, discusses the recent progress in the landscape of HER2-positive breast cancer and what she envisions future treatment approaches will be for patients.

Dr. Barcenas on Neratinib-Related Diarrhea in HER2+ Breast Cancer

February 4th 2017

Carlos Barcenas, MD, assistant professor, Department of Breast Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, discusses side effects of neratinib in patients with HER2-positive early-stage breast cancer.

Dr. Loibl Discusses GeparSepto Trial in Breast Cancer

February 4th 2017

Sibylle Loibl, MD, PhD, co-chair of the German Breast Group (GBG) and associate professor at the University of Frankfurt, discusses the GeparSepto trial in subgroups of patients with breast cancer.

Ribociclib Both Active and Safe in Elderly Patients With HR+/HER2- Breast Cancer

February 3rd 2017

Ribociclib, an orally bioavailable, selective cyclin-dependent kinase 4/6 inhibitor, demonstrated similar clinical benefits and safety profiles for both elderly and younger patients with hormone-receptor positive, human epidermal growth factor receptor-2 negative advanced breast cancer.

Dr. Sanft on Sequencing of Treatments for HER2+ Breast Cancer

February 3rd 2017

Tara Sanft, MD, assistant professor of Medicine, medical director of Adult Survivorship for Yale Cancer Center Survivorship Clinic, discusses sequencing of treatments for patients with HER2-positive breast cancer.

Trial Explores Eliminating Breast Cancer Surgery in Exceptional Responders to Neoadjuvant Therapy

February 2nd 2017

Henry M. Kuerer, MD, PhD, discusses surgical advancements in the field of breast cancer and the goals of a phase II single-center trial and how it could impact these exceptional responders.

Expert Shares Insight on Patient Selection for RT in Breast Cancer

February 2nd 2017

Welela Tereffe, MD, discusses the current state of radiation therapy in breast cancer and the importance of a multidisciplinary approach.

Dr. Brufsky on the COLET Trial for Triple-Negative Breast Cancer

February 2nd 2017

Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses the COLET trial combining cobimetinib (Cotellic) and paclitaxel (Abraxane) as a treatment for patients with triple-negative breast cancer (TNBC).

Meta-Analysis Highlights Nab-Paclitaxel Activity Across Subgroups of Breast Cancer

February 1st 2017

Treatment with nanoparticle albumin-bound nab-paclitaxel showed encouraging activity across different subgroups of patients with breast cancer, according to the results of a meta-analysis of several clinical trials.

Molecular Testing in Breast Cancer to Answer More Questions in 2017

January 31st 2017

Jenny C. Chang, MD, discusses the significance of molecular testing in breast cancer and how it will lead to an improvement in treatment approaches in 2017 and beyond.

Making the Cancer Journey Tolerable: Loprinzi Puts Focus on Symptoms

January 26th 2017

Charles L. Loprinzi, MD may have landed somewhat accidentally into the world of symptom management research, but once he arrived, he was there to stay.